The E2F-regulated gene Chk1 is highly expressed in triple-negative estrogen receptor-/progesterone receptor-/HER-2-: Breast carcinomas

被引:129
作者
Verlinden, Lieve
Bempt, Isabelle Vanden
Eelen, Guy
Drijkoningen, Maria
Verlinden, Ilse
Marchal, Kathleen
De Wolf-Peeters, Christiane
Christiaens, Marie-Rose
Michiels, Luc
Bouillon, Roger
Verstuyf, Annernieke
机构
[1] Katholieke Univ Leuven, Lab Expt Geneeskunde & Endocrinol, B-3000 Louvain, Belgium
[2] Katholieke Univ Leuven, CMPG ESAT, Louvain, Belgium
[3] Katholieke Univ Leuven, Univ Hosp, Dept Pathol, Louvain, Belgium
[4] Katholieke Univ Leuven, Univ Hosp, Multidisciplinary Breast Ctr, Louvain, Belgium
[5] Katholieke Univ Leuven, Univ Hosp, Dept Surg, Louvain, Belgium
[6] Univ Hasselt, Biomed Res Inst BIOMED, Diepenbeek, Belgium
关键词
D O I
10.1158/0008-5472.CAN-06-3545
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We previously showed that checkpoint kinase 1 (Chk1) and Claspin, two DNA-damage checkpoint proteins, were down-regulated by 1,25-dihydroxyvitamin D-3, a known inhibitor of cell proliferation. In the present study, we aimed to investigate the transcriptional regulation of Chk1 and Claspin and to study their expression levels in human breast cancer tissue. Transient transfection experiments in MCF-7 breast cancer cells showed that promoter activities of Chk1 and Claspin were regulated by the E2F family of transcription factors. Subsequently, transcript levels of Chk1, Claspin, and E2F1 were determined by quantitative reverse transcriptase-PCR analysis in 103 primary invasive breast carcinomas and were compared with several clinicopathologic variables in breast cancer. A strong correlation was found between Chk1 and Claspin transcript levels. Transcript levels of Chk1, Claspin, and E2F] were highest in histologic grade 3 tumors and in tumors in which the expression of estrogen receptor (ER) and progesterone receptor (PR) was lost. Moreover, Chk1 expression was significantly elevated in grade 3 breast carcinomas showing a triple-negative ER-/PR-/HER-2- phenotype compared with other grade 3 tumors. Further research is warranted to validate the use of Chk1 inhibitors in triple-negative breast carcinomas for which treatment strategies are limited at present.
引用
收藏
页码:6574 / 6581
页数:8
相关论文
共 45 条
[31]   Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications [J].
Sorlie, T ;
Perou, CM ;
Tibshirani, R ;
Aas, T ;
Geisler, S ;
Johnsen, H ;
Hastie, T ;
Eisen, MB ;
van de Rijn, M ;
Jeffrey, SS ;
Thorsen, T ;
Quist, H ;
Matese, JC ;
Brown, PO ;
Botstein, D ;
Lonning, PE ;
Borresen-Dale, AL .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (19) :10869-10874
[32]   Breast cancer classification and prognosis based on gene expression profiles from a population-based study [J].
Sotiriou, C ;
Neo, SY ;
McShane, LM ;
Korn, EL ;
Long, PM ;
Jazaeri, A ;
Martiat, P ;
Fox, SB ;
Harris, AL ;
Liu, ET .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (18) :10393-10398
[33]   Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies [J].
Spector, NL ;
Xia, WL ;
Burris, H ;
Hurwitz, H ;
Dees, EC ;
Dowlati, A ;
O'Neil, B ;
Overmoyer, B ;
Marcom, PK ;
Blackwell, KL ;
Smith, DA ;
Koch, KM ;
Stead, A ;
Mangum, S ;
Ellis, MJ ;
Liu, LH ;
Man, AK ;
Bremer, TM ;
Harris, J ;
Bacus, S .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (11) :2502-2512
[34]  
Tao Zhi-Fu, 2006, Anti-Cancer Agents in Medicinal Chemistry, V6, P377, DOI 10.2174/187152006777698132
[35]   The basal phenotype of BRCA1-related breast cancer - Past, present and future [J].
Tischkowitz, MD ;
Foulkes, WD .
CELL CYCLE, 2006, 5 (09) :963-967
[36]   Checkpoint kinase 1 (CHK1) protein and mRNA expression is downregulated in aggressive variants of human lymphoid neoplasms [J].
Tort, F ;
Hernández, S ;
Beà, S ;
Camacho, E ;
Fernández, V ;
Esteller, M ;
Fraga, MF ;
Burek, C ;
Rosenwald, A ;
Hernández, L ;
Campo, E .
LEUKEMIA, 2005, 19 (01) :112-117
[37]   Ki-67 expression in breast carcinoma - Its association with grading systems, clinical parameters, and other prognostic factors - A surrogate marker? [J].
Trihia, H ;
Murray, S ;
Price, K ;
Gelber, RD ;
Golouh, R ;
Goldhirsch, A ;
Coates, AS ;
Collins, J ;
Castiglione-Gertsch, M ;
Gusterson, BA .
CANCER, 2003, 97 (05) :1321-1331
[38]   CHIR-124, a novel potent inhibitor of Chk1, potentiates the cytotoxicity of topoisomerase I poisons in vitro and in vivo [J].
Tse, Archie N. ;
Rendahl, Katherine G. ;
Sheikh, Tahir ;
Cheema, Haider ;
Aardalen, Kim ;
Embry, Millicent ;
Ma, Sylvia ;
Moler, Edward J. ;
Ni, Zhi Jie ;
de Menezes, Daniel E. Lopes ;
Hibner, Barbara ;
Gesner, Thomas G. ;
Schwartz, Gary K. .
CLINICAL CANCER RESEARCH, 2007, 13 (02) :591-602
[39]   Evaluation of claspin as a proliferation marker in human cancer and normal tissues [J].
Tsimaratou, K. ;
Kletsas, D. ;
Kastrinakis, N. G. ;
Tsantoulis, P. K. ;
Evangelou, K. ;
Sideridou, M. ;
Liontos, M. ;
Poulias, I. ;
Venere, M. ;
Salmas, M. ;
Kittas, C. ;
Halazonetis, T. D. ;
Gorgoulis, V. G. .
JOURNAL OF PATHOLOGY, 2007, 211 (03) :331-339
[40]   Large, central acellular zones indicating myoepithelial tumor differentiation in high-grade invasive ductal carcinomas as markers of predisposition to lung and brain metastases [J].
Tsuda, H ;
Takarabe, T ;
Hasegawa, F ;
Fukutomi, T ;
Hirohashi, S .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2000, 24 (02) :197-202